SCHEMBL8980792

SCHEMBL8980792

CNN(C)c1ccc(OC)nc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OXTR P30559 5/20 0.44
NNMT P40261 1/20 0.40
AVPR1A P37288 1/20 0.39
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
CYP2A6 P11509 1/20 0.38
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM1A O60341 1/20 0.37
LMNA P02545 2/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8981848 0.82 MAPT (0.44) OXTRMAPTHTT
SCHEMBL19965670 0.80 OXTR (0.49) OXTRNNMTAVPR1AHSD17B1HSD17B2
SCHEMBL8981706 0.77 EDNRA (0.35) KDM4EMAPTNPC1ALDH1A1
SCHEMBL7672381 0.75 OXTR (0.49) OXTRNNMTAVPR1AHSD17B1HSD17B2
SCHEMBL8981850 0.75 HDAC1 (0.36) CYP2A6KDM4EKDM1ANPC1ALDH1A1
SCHEMBL5182975 0.71 OXTR (0.44) OXTRNNMTAVPR1AKMT2AKDM1A
SCHEMBL11803312 0.70 OXTR (0.58) OXTRNNMTAVPR1AKDM4EMEN1
SCHEMBL6823222 0.70 CA1 (0.50) KDM4EMAPTNPC1ALDH1A1HTT
SCHEMBL1238891 0.69 OXTR (0.41) OXTRNNMTAVPR1AMEN1KMT2A
SCHEMBL8981687 0.69 TRPV4 (0.46) KDM4EMEN1MAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD OXTR 1401/4885NNMT 585/4885AVPR1A 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.